0
Research
Retrospective financial analysis of a herpes zoster vaccination program from an independent community pharmacy perspective
Heidi M. Wood, PharmD; Randal P. McDonough, MS, PharmD; William R. Doucette, PhD
J Am Pharm Assoc (2003) 2009;49:12-17. doi:10.1331/JAPhA.2009.08030

Abstract

Objective  To determine the net financial gain or loss for herpes zoster vaccination services provided to patients from the perspective of an independent community pharmacy.

Design  Retrospective review of pharmacy records over the program's initial 11-month period.

Setting  Independent community pharmacy in Iowa City, IA.

Participants  Patients received immunization with the herpes zoster vaccine from a certified pharmacist.

Intervention  Herpes zoster vaccination services were provided to the patient and documented by the pharmacist.

Main outcome measure  Net financial gains or losses were calculated for the herpes zoster vaccination program. Sensitivity analyses were based on costs that might be incurred during program start-up.

Results  478 patients received zoster vaccination services over the initial 11-month period. A net financial gain for the herpes zoster vaccination program was achieved, with a net profit of $15.02, or 8.15%, per vaccination.

Conclusion  Revenues for this vaccination program exceeded its costs from the independent community pharmacy perspective.

Sign In
APhA Members 
Welcome to JAPhA.org! Please log in below using your APhA username and password. Update your APhA profile.
Not a Subscriber
New to JAPhA? Become an APhA member to receive a full subscription to both the print and online editions.

OR

Register for a FREE limited account to benefit from personalization features such as alerts.

References

Kockler DR, McCarthy MW. Zoster vaccine live Pharmacotherapy. 2007;27:1013–9.[PubMed][CrossRef]
 
Insinga RP, Itzler RF, Pellissier JM. Acute/subacute herpes zoster: Healthcare resource utilization and costs in a group of U.S. health plans Pharmacoeconomics. 2007;25:155–69.[PubMed]
 
Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Vaccine. 2007;25:8326–37.[PubMed]
 
Gershon AA. Vaccination to prevent zoster in the elderly Epidemiol Infect. 2007;135:883–6.[PubMed]
 
Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Clin Infect Dis. 2007;44:1280–8.[PubMed]
 
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults N Engl J Med. 2005;352:2271–84.[PubMed]
 
 Zostavax [package insert]. Whitehouse Station, NJ:  Merck & Co., Inc.:  2007.
 
 Centers for Disease Control and Prevention. ACIP provisional recommendations for the use of zoster vaccine Accessed at www.cdc.gov/vaccines/recs/provisional/downloads/zoster-11-20-06.pdf, January 18,  2008.
 
Grabenstein JD, Guess HA, Hartzema AG, et al. Effect of vaccination by community pharmacists among adult prescription recipients Med Care. 2001;39:340–8.[PubMed]
 
 Anonymous. The shingles vaccine: Why hasn't it caught on? The cost and other factors are to blame Harv Health Lett. 2007;32:1–2.
 
Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Ann Intern Med. 2006;145:317–25.[PubMed]
 
West DS, ed.  NCPA—Pfizer Digest 2007. Alexandria, VA:  National Community Pharmacists Association;  2007.
 
Gardner JS. A practical guide to establishing vaccine administration services in community pharmacies J Am Pharm Assoc. 1997;NS37:683–93.
 
McDonough RP, Doucette WR. Using personal selling skills to promote pharmacy services J Am Pharm Assoc. 2003;43:363–74.
 
 Centers for Medicare and Medicaid Services. Reimbursement for vaccines and vaccine administration under Medicare Part D Accessed at www.cms.hhs.gov/MLNMattersArticles/downloads/SE0727.pdf, January 18,  2008.
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Please read the other comments before you post yours. Comments are moderated and will appear on the site at the discertion of the editorial staff.
* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content

Customize your page view by dragging & repositioning the boxes below.

JAPhA Articles
Topic Collections
PubMed Articles
Advertisement
 
  • Print
  • PDF Download
  • Email
  • Share
  • Get Citation
  • Submit Comment
  • Article Alerts
    Please Wait... Processing your request... Please Wait.
    You must sign in to sign-up for alerts.

    Please confirm that your email address is correct, so you can successfully receive this alert.

  • Letters To Editor
  • Reprints